Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$67.37 USD

67.37
1,569,064

-1.02 (-1.49%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $67.49 +0.12 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Company News for Apr 24, 2018

by Zacks Equity Research

Companies in the news are: ALK,ASB,HSIC,HUM

    Zacks Equity Research

    Factors Setting Stage for CVS Health's (CVS) Q1 Earnings

    by Zacks Equity Research

    CVS Health (CVS) expects robust 2018 PBM selling season and strong Pharmacy Services segment to drive earnings in Q1.

      Zacks Equity Research

      Can Steady Overall Growth Drive Align's (ALGN) Q1 Earnings?

      by Zacks Equity Research

      Align Technology (ALGN) is likely to gain from strength in the Invisalign space as well as Scanner and Service business in Q1.

        Zacks Equity Research

        Can LaunchPad Aid LabCorp's (LH) Covance Arm in Q1 Earnings?

        by Zacks Equity Research

        Labcorp's (LH) multi-year LaunchPad project holds enough promise for growth. Good news is that the company already grossed savings worth $20 million from the same in 2017.

          Zacks Equity Research

          Can S.E.T. Aid Zimmer (ZBH) Q1 Earnings Despite Supply Woes?

          by Zacks Equity Research

          Several FDA clearances within S.E.T since last November raise hope for Zimmer Biomet (ZBH) in Q1.

            Zacks Equity Research

            What's in the Offing for Thermo Fisher (TMO) in Q1 Earnings?

            by Zacks Equity Research

            Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.

              Zacks Equity Research

              Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings?

              by Zacks Equity Research

              Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other segments in Q1.

                Zacks Equity Research

                WATCHMAN to Aid Boston Scientific (BSX) Q1 Earnings Amid Woes

                by Zacks Equity Research

                The WATCHMAN platform is expected to experience a strong quarter on consistent global momentum as Boston Scientific's (BSX) multiple market development efforts continue to push for growth.

                  Zacks Equity Research

                  Will Edwards' (EW) Growth in All Lines Drive Q1 Earnings?

                  by Zacks Equity Research

                  Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.

                    Zacks Equity Research

                    Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?

                    by Zacks Equity Research

                    Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.

                      Zacks Equity Research

                      Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?

                      by Zacks Equity Research

                      Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.

                        Zacks Equity Research

                        What's in Store for GNC Holdings (GNC) This Earnings Season?

                        by Zacks Equity Research

                        GNC Holdings (GNC) likely to witness year-over-year decline in revenues owing to weakness in the U.S. & Canada and Manufacturing/Wholesale segments in Q1.

                          Zacks Equity Research

                          Henry Schein Ties Up With Internet Brands to Boost Dental Arm

                          by Zacks Equity Research

                          Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.

                            Gargi Seth headshot

                            Dental Implant & Prosthetic Boom Puts Spotlight on 3 Stocks

                            by Gargi Seth

                            The dental market has outperformed the broader market in last ten years on the back of demand from both teenagers and adults.

                              Zacks Equity Research

                              Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?

                              by Zacks Equity Research

                              Walgreens Boots' (WBA) increase in sales at the Retail Pharmacy International segment, on account of the company's strategic tie-ups, along with strength in other businesses buoy optimism.

                                Zacks Equity Research

                                Is Henry Schein (HSIC) a Viable Stock for Value Investors?

                                by Zacks Equity Research

                                Henry Schein (HSIC) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.

                                  Zacks Equity Research

                                  Henry Schein (HSIC) Down 3.3% Since Earnings Report: Can It Rebound?

                                  by Zacks Equity Research

                                  Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Zacks Equity Research

                                    Henry Schien to Distribute Grifols Product in United States

                                    by Zacks Equity Research

                                    We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.

                                      Zacks Equity Research

                                      Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat

                                      by Zacks Equity Research

                                      Henry Schein's (HSIC) strong share gains in the North American and overseas markets along with solid revenues raise optimism.

                                        Zacks Equity Research

                                        Henry Schein (HSIC) Q4 Earnings in Line, Revenues Beat

                                        by Zacks Equity Research

                                        Henry Schein's (HSIC) four global segments gained solid market share during Q4 and delivered solid earnings growth.

                                          Zacks Equity Research

                                          Henry Schein (HSIC) Q4 Earnings to Show Growth in All Lines?

                                          by Zacks Equity Research

                                          Henry Schein (HSIC) likely to gain on strength across all business segments in Q4.

                                            Zacks Equity Research

                                            What's in Store for GNC Holdings (GNC) This Earnings Season?

                                            by Zacks Equity Research

                                            GNC Holdings (GNC) likely to see decline in year-over-year revenues owing to weakness in U.S. & Canada segment in Q4.

                                              Zacks Equity Research

                                              Will Covance Drug Development Drive LabCorp (LH) Q4 Earnings?

                                              by Zacks Equity Research

                                              LabCorp (LH) is expected to gain from LabCorp Diagnostics and Covance Drug Development segments in Q4.

                                                Zacks Equity Research

                                                Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?

                                                by Zacks Equity Research

                                                Myriad (MYGN) positioned to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.

                                                  Zacks Equity Research

                                                  Is AmerisourceBergen (ABC) Poised for a Beat in Q1 Earnings?

                                                  by Zacks Equity Research

                                                  AmerisourceBergen's (ABC) Q1 results are expected to gain on strength in pharmaceutical distribution segment.